nodes	percent_of_prediction	percent_of_DWPC	metapath
Pseudoephedrine—IL2—multiple sclerosis	0.551	0.748	CbGaD
Pseudoephedrine—TNF—multiple sclerosis	0.186	0.252	CbGaD
Pseudoephedrine—Cerebral haemorrhage—Fingolimod—multiple sclerosis	0.00279	0.07	CcSEcCtD
Pseudoephedrine—SLC6A3—nerve—multiple sclerosis	0.00205	0.0548	CbGeAlD
Pseudoephedrine—NFATC1—nervous system—multiple sclerosis	0.0019	0.051	CbGeAlD
Pseudoephedrine—NFATC1—central nervous system—multiple sclerosis	0.00183	0.0491	CbGeAlD
Pseudoephedrine—NFATC1—cerebellum—multiple sclerosis	0.00179	0.048	CbGeAlD
Pseudoephedrine—IL2—nervous system—multiple sclerosis	0.00174	0.0467	CbGeAlD
Pseudoephedrine—IL2—central nervous system—multiple sclerosis	0.00168	0.0449	CbGeAlD
Pseudoephedrine—SLC6A2—nerve—multiple sclerosis	0.00165	0.0442	CbGeAlD
Pseudoephedrine—MAOA—nerve—multiple sclerosis	0.00152	0.0408	CbGeAlD
Pseudoephedrine—ADRA2A—peripheral nervous system—multiple sclerosis	0.0015	0.0401	CbGeAlD
Pseudoephedrine—NFATC1—brain—multiple sclerosis	0.00146	0.039	CbGeAlD
Pseudoephedrine—IL2—brain—multiple sclerosis	0.00133	0.0357	CbGeAlD
Pseudoephedrine—SLC6A3—brainstem—multiple sclerosis	0.000878	0.0235	CbGeAlD
Pseudoephedrine—SLC6A4—brainstem—multiple sclerosis	0.000805	0.0216	CbGeAlD
Pseudoephedrine—Bradycardia—Fingolimod—multiple sclerosis	0.00079	0.0198	CcSEcCtD
Pseudoephedrine—SLC6A2—brainstem—multiple sclerosis	0.000709	0.019	CbGeAlD
Pseudoephedrine—ADRA1A—brainstem—multiple sclerosis	0.000659	0.0177	CbGeAlD
Pseudoephedrine—MAOA—brainstem—multiple sclerosis	0.000653	0.0175	CbGeAlD
Pseudoephedrine—MAOA—retina—multiple sclerosis	0.00063	0.0169	CbGeAlD
Pseudoephedrine—Palpitations—Fingolimod—multiple sclerosis	0.000597	0.015	CcSEcCtD
Pseudoephedrine—Hypertension—Fingolimod—multiple sclerosis	0.000583	0.0146	CcSEcCtD
Pseudoephedrine—SLC6A3—midbrain—multiple sclerosis	0.00056	0.015	CbGeAlD
Pseudoephedrine—SLC6A3—spinal cord—multiple sclerosis	0.000546	0.0146	CbGeAlD
Pseudoephedrine—SLC6A4—midbrain—multiple sclerosis	0.000513	0.0137	CbGeAlD
Pseudoephedrine—SLC6A4—spinal cord—multiple sclerosis	0.0005	0.0134	CbGeAlD
Pseudoephedrine—SLC6A2—medulla oblongata—multiple sclerosis	0.000494	0.0132	CbGeAlD
Pseudoephedrine—Dyspnoea—Fingolimod—multiple sclerosis	0.000492	0.0123	CcSEcCtD
Pseudoephedrine—SLC6A3—nervous system—multiple sclerosis	0.00046	0.0123	CbGeAlD
Pseudoephedrine—MAOA—medulla oblongata—multiple sclerosis	0.000455	0.0122	CbGeAlD
Pseudoephedrine—SLC6A3—central nervous system—multiple sclerosis	0.000443	0.0119	CbGeAlD
Pseudoephedrine—ADRB1—nervous system—multiple sclerosis	0.000436	0.0117	CbGeAlD
Pseudoephedrine—SLC6A3—cerebellum—multiple sclerosis	0.000433	0.0116	CbGeAlD
Pseudoephedrine—SLC6A4—nervous system—multiple sclerosis	0.000422	0.0113	CbGeAlD
Pseudoephedrine—ADRB1—central nervous system—multiple sclerosis	0.00042	0.0113	CbGeAlD
Pseudoephedrine—MAOA—midbrain—multiple sclerosis	0.000416	0.0112	CbGeAlD
Pseudoephedrine—SLC6A4—central nervous system—multiple sclerosis	0.000406	0.0109	CbGeAlD
Pseudoephedrine—Euphoric mood—Prednisolone—multiple sclerosis	0.000406	0.0102	CcSEcCtD
Pseudoephedrine—MAOA—spinal cord—multiple sclerosis	0.000406	0.0109	CbGeAlD
Pseudoephedrine—Delirium—Prednisone—multiple sclerosis	0.000399	0.01	CcSEcCtD
Pseudoephedrine—Asthenia—Fingolimod—multiple sclerosis	0.000396	0.00991	CcSEcCtD
Pseudoephedrine—Arrhythmia—Cladribine—multiple sclerosis	0.000393	0.00985	CcSEcCtD
Pseudoephedrine—CYP2D6—brainstem—multiple sclerosis	0.000388	0.0104	CbGeAlD
Pseudoephedrine—Euphoric mood—Triamcinolone—multiple sclerosis	0.000373	0.00935	CcSEcCtD
Pseudoephedrine—Euphoric mood—Methylprednisolone—multiple sclerosis	0.000372	0.00933	CcSEcCtD
Pseudoephedrine—SLC6A2—nervous system—multiple sclerosis	0.000371	0.00995	CbGeAlD
Pseudoephedrine—Dizziness—Fingolimod—multiple sclerosis	0.000365	0.00914	CcSEcCtD
Pseudoephedrine—SLC6A2—central nervous system—multiple sclerosis	0.000357	0.00958	CbGeAlD
Pseudoephedrine—SLC6A3—brain—multiple sclerosis	0.000352	0.00943	CbGeAlD
Pseudoephedrine—ADRA2A—medulla oblongata—multiple sclerosis	0.000349	0.00936	CbGeAlD
Pseudoephedrine—Headache—Fingolimod—multiple sclerosis	0.000345	0.00866	CcSEcCtD
Pseudoephedrine—ADRA1A—nervous system—multiple sclerosis	0.000345	0.00925	CbGeAlD
Pseudoephedrine—MAOA—nervous system—multiple sclerosis	0.000342	0.00917	CbGeAlD
Pseudoephedrine—Euphoric mood—Betamethasone—multiple sclerosis	0.000339	0.00849	CcSEcCtD
Pseudoephedrine—Euphoric mood—Dexamethasone—multiple sclerosis	0.000339	0.00849	CcSEcCtD
Pseudoephedrine—ADRB1—brain—multiple sclerosis	0.000334	0.00894	CbGeAlD
Pseudoephedrine—ADRA1A—central nervous system—multiple sclerosis	0.000332	0.00891	CbGeAlD
Pseudoephedrine—MAOA—central nervous system—multiple sclerosis	0.000329	0.00883	CbGeAlD
Pseudoephedrine—Chest pain—Cladribine—multiple sclerosis	0.000326	0.00817	CcSEcCtD
Pseudoephedrine—Anxiety—Cladribine—multiple sclerosis	0.000325	0.00814	CcSEcCtD
Pseudoephedrine—ADRA1A—cerebellum—multiple sclerosis	0.000325	0.0087	CbGeAlD
Pseudoephedrine—SLC6A4—brain—multiple sclerosis	0.000322	0.00864	CbGeAlD
Pseudoephedrine—MAOA—cerebellum—multiple sclerosis	0.000322	0.00863	CbGeAlD
Pseudoephedrine—Arrhythmia—Azathioprine—multiple sclerosis	0.00032	0.00801	CcSEcCtD
Pseudoephedrine—ADRA2A—midbrain—multiple sclerosis	0.000319	0.00855	CbGeAlD
Pseudoephedrine—Confusional state—Cladribine—multiple sclerosis	0.000315	0.0079	CcSEcCtD
Pseudoephedrine—ADRA2A—spinal cord—multiple sclerosis	0.000311	0.00835	CbGeAlD
Pseudoephedrine—Sweating—Mitoxantrone—multiple sclerosis	0.000309	0.00774	CcSEcCtD
Pseudoephedrine—Psychotic disorder—Methylprednisolone—multiple sclerosis	0.000307	0.0077	CcSEcCtD
Pseudoephedrine—Tachycardia—Cladribine—multiple sclerosis	0.000305	0.00764	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Cladribine—multiple sclerosis	0.000302	0.00757	CcSEcCtD
Pseudoephedrine—Irritability—Methylprednisolone—multiple sclerosis	0.0003	0.00753	CcSEcCtD
Pseudoephedrine—Anorexia—Cladribine—multiple sclerosis	0.000298	0.00747	CcSEcCtD
Pseudoephedrine—Euphoric mood—Prednisone—multiple sclerosis	0.000295	0.00739	CcSEcCtD
Pseudoephedrine—Bradycardia—Mitoxantrone—multiple sclerosis	0.000294	0.00738	CcSEcCtD
Pseudoephedrine—SLC6A2—brain—multiple sclerosis	0.000284	0.0076	CbGeAlD
Pseudoephedrine—Insomnia—Cladribine—multiple sclerosis	0.000283	0.00708	CcSEcCtD
Pseudoephedrine—Psychotic disorder—Dexamethasone—multiple sclerosis	0.000279	0.007	CcSEcCtD
Pseudoephedrine—Psychotic disorder—Betamethasone—multiple sclerosis	0.000279	0.007	CcSEcCtD
Pseudoephedrine—Dyspnoea—Cladribine—multiple sclerosis	0.000279	0.00698	CcSEcCtD
Pseudoephedrine—Irritability—Dexamethasone—multiple sclerosis	0.000273	0.00684	CcSEcCtD
Pseudoephedrine—Irritability—Betamethasone—multiple sclerosis	0.000273	0.00684	CcSEcCtD
Pseudoephedrine—Decreased appetite—Cladribine—multiple sclerosis	0.000272	0.00681	CcSEcCtD
Pseudoephedrine—Pain—Cladribine—multiple sclerosis	0.000267	0.0067	CcSEcCtD
Pseudoephedrine—ADRA1A—brain—multiple sclerosis	0.000264	0.00707	CbGeAlD
Pseudoephedrine—ADRA2A—nervous system—multiple sclerosis	0.000262	0.00703	CbGeAlD
Pseudoephedrine—MAOA—brain—multiple sclerosis	0.000261	0.00701	CbGeAlD
Pseudoephedrine—Arrhythmia—Mitoxantrone—multiple sclerosis	0.000258	0.00647	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Cladribine—multiple sclerosis	0.000258	0.00645	CcSEcCtD
Pseudoephedrine—ADRA2A—central nervous system—multiple sclerosis	0.000253	0.00677	CbGeAlD
Pseudoephedrine—Body temperature increased—Cladribine—multiple sclerosis	0.000247	0.00619	CcSEcCtD
Pseudoephedrine—ADRA2A—cerebellum—multiple sclerosis	0.000247	0.00662	CbGeAlD
Pseudoephedrine—Psychotic disorder—Prednisone—multiple sclerosis	0.000243	0.0061	CcSEcCtD
Pseudoephedrine—Bradycardia—Prednisolone—multiple sclerosis	0.000242	0.00605	CcSEcCtD
Pseudoephedrine—Irritability—Prednisone—multiple sclerosis	0.000238	0.00596	CcSEcCtD
Pseudoephedrine—Sweating—Methylprednisolone—multiple sclerosis	0.000232	0.00583	CcSEcCtD
Pseudoephedrine—Asthenia—Cladribine—multiple sclerosis	0.000224	0.00562	CcSEcCtD
Pseudoephedrine—Bradycardia—Triamcinolone—multiple sclerosis	0.000222	0.00557	CcSEcCtD
Pseudoephedrine—Bradycardia—Methylprednisolone—multiple sclerosis	0.000222	0.00555	CcSEcCtD
Pseudoephedrine—Hypertension—Mitoxantrone—multiple sclerosis	0.000217	0.00545	CcSEcCtD
Pseudoephedrine—Hallucination—Methylprednisolone—multiple sclerosis	0.000217	0.00543	CcSEcCtD
Pseudoephedrine—Chest pain—Mitoxantrone—multiple sclerosis	0.000214	0.00537	CcSEcCtD
Pseudoephedrine—Anxiety—Mitoxantrone—multiple sclerosis	0.000214	0.00535	CcSEcCtD
Pseudoephedrine—Arrhythmia—Prednisolone—multiple sclerosis	0.000212	0.00531	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Azathioprine—multiple sclerosis	0.000209	0.00525	CcSEcCtD
Pseudoephedrine—Confusional state—Mitoxantrone—multiple sclerosis	0.000207	0.00519	CcSEcCtD
Pseudoephedrine—Dizziness—Cladribine—multiple sclerosis	0.000207	0.00518	CcSEcCtD
Pseudoephedrine—CYP2D6—nervous system—multiple sclerosis	0.000203	0.00545	CbGeAlD
Pseudoephedrine—Bradycardia—Betamethasone—multiple sclerosis	0.000202	0.00505	CcSEcCtD
Pseudoephedrine—Bradycardia—Dexamethasone—multiple sclerosis	0.000202	0.00505	CcSEcCtD
Pseudoephedrine—Body temperature increased—Azathioprine—multiple sclerosis	0.000201	0.00503	CcSEcCtD
Pseudoephedrine—ADRA2A—brain—multiple sclerosis	0.000201	0.00538	CbGeAlD
Pseudoephedrine—Tachycardia—Mitoxantrone—multiple sclerosis	0.000201	0.00502	CcSEcCtD
Pseudoephedrine—Irritability—Methotrexate—multiple sclerosis	0.000199	0.00498	CcSEcCtD
Pseudoephedrine—Vomiting—Cladribine—multiple sclerosis	0.000199	0.00498	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Mitoxantrone—multiple sclerosis	0.000199	0.00498	CcSEcCtD
Pseudoephedrine—Rash—Cladribine—multiple sclerosis	0.000197	0.00494	CcSEcCtD
Pseudoephedrine—Hallucination—Dexamethasone—multiple sclerosis	0.000197	0.00494	CcSEcCtD
Pseudoephedrine—Hallucination—Betamethasone—multiple sclerosis	0.000197	0.00494	CcSEcCtD
Pseudoephedrine—Dermatitis—Cladribine—multiple sclerosis	0.000197	0.00493	CcSEcCtD
Pseudoephedrine—Anorexia—Mitoxantrone—multiple sclerosis	0.000196	0.00491	CcSEcCtD
Pseudoephedrine—Headache—Cladribine—multiple sclerosis	0.000196	0.00491	CcSEcCtD
Pseudoephedrine—CYP2D6—central nervous system—multiple sclerosis	0.000196	0.00524	CbGeAlD
Pseudoephedrine—Arrhythmia—Triamcinolone—multiple sclerosis	0.000195	0.00488	CcSEcCtD
Pseudoephedrine—Arrhythmia—Methylprednisolone—multiple sclerosis	0.000194	0.00487	CcSEcCtD
Pseudoephedrine—CYP2D6—cerebellum—multiple sclerosis	0.000191	0.00513	CbGeAlD
Pseudoephedrine—Nausea—Cladribine—multiple sclerosis	0.000186	0.00465	CcSEcCtD
Pseudoephedrine—Vertigo—Prednisolone—multiple sclerosis	0.000186	0.00465	CcSEcCtD
Pseudoephedrine—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000183	0.00459	CcSEcCtD
Pseudoephedrine—Dyspepsia—Mitoxantrone—multiple sclerosis	0.000181	0.00453	CcSEcCtD
Pseudoephedrine—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000179	0.00448	CcSEcCtD
Pseudoephedrine—Hypertension—Prednisolone—multiple sclerosis	0.000178	0.00447	CcSEcCtD
Pseudoephedrine—Arrhythmia—Dexamethasone—multiple sclerosis	0.000177	0.00443	CcSEcCtD
Pseudoephedrine—Arrhythmia—Betamethasone—multiple sclerosis	0.000177	0.00443	CcSEcCtD
Pseudoephedrine—Pain—Mitoxantrone—multiple sclerosis	0.000176	0.0044	CcSEcCtD
Pseudoephedrine—Bradycardia—Prednisone—multiple sclerosis	0.000176	0.0044	CcSEcCtD
Pseudoephedrine—Hallucination—Prednisone—multiple sclerosis	0.000172	0.0043	CcSEcCtD
Pseudoephedrine—Vertigo—Triamcinolone—multiple sclerosis	0.000171	0.00428	CcSEcCtD
Pseudoephedrine—Vertigo—Methylprednisolone—multiple sclerosis	0.00017	0.00427	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000169	0.00424	CcSEcCtD
Pseudoephedrine—Dysuria—Methotrexate—multiple sclerosis	0.000168	0.00422	CcSEcCtD
Pseudoephedrine—Dizziness—Azathioprine—multiple sclerosis	0.000168	0.00421	CcSEcCtD
Pseudoephedrine—Tachycardia—Prednisolone—multiple sclerosis	0.000165	0.00412	CcSEcCtD
Pseudoephedrine—Hypertension—Triamcinolone—multiple sclerosis	0.000164	0.00411	CcSEcCtD
Pseudoephedrine—Hypertension—Methylprednisolone—multiple sclerosis	0.000164	0.0041	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000163	0.00408	CcSEcCtD
Pseudoephedrine—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000162	0.00407	CcSEcCtD
Pseudoephedrine—Vomiting—Azathioprine—multiple sclerosis	0.000162	0.00405	CcSEcCtD
Pseudoephedrine—Anxiety—Methylprednisolone—multiple sclerosis	0.000161	0.00403	CcSEcCtD
Pseudoephedrine—Rash—Azathioprine—multiple sclerosis	0.00016	0.00402	CcSEcCtD
Pseudoephedrine—Dermatitis—Azathioprine—multiple sclerosis	0.00016	0.00401	CcSEcCtD
Pseudoephedrine—Headache—Azathioprine—multiple sclerosis	0.000159	0.00399	CcSEcCtD
Pseudoephedrine—Confusional state—Methylprednisolone—multiple sclerosis	0.000156	0.00391	CcSEcCtD
Pseudoephedrine—CYP2D6—brain—multiple sclerosis	0.000155	0.00416	CbGeAlD
Pseudoephedrine—Vertigo—Dexamethasone—multiple sclerosis	0.000155	0.00388	CcSEcCtD
Pseudoephedrine—Vertigo—Betamethasone—multiple sclerosis	0.000155	0.00388	CcSEcCtD
Pseudoephedrine—Arrhythmia—Prednisone—multiple sclerosis	0.000154	0.00386	CcSEcCtD
Pseudoephedrine—Sweating—Methotrexate—multiple sclerosis	0.000154	0.00386	CcSEcCtD
Pseudoephedrine—Insomnia—Prednisolone—multiple sclerosis	0.000152	0.00382	CcSEcCtD
Pseudoephedrine—Tachycardia—Triamcinolone—multiple sclerosis	0.000151	0.00379	CcSEcCtD
Pseudoephedrine—Nausea—Azathioprine—multiple sclerosis	0.000151	0.00378	CcSEcCtD
Pseudoephedrine—Tachycardia—Methylprednisolone—multiple sclerosis	0.000151	0.00378	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.00015	0.00376	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.00015	0.00375	CcSEcCtD
Pseudoephedrine—Hypertension—Dexamethasone—multiple sclerosis	0.000149	0.00373	CcSEcCtD
Pseudoephedrine—Hypertension—Betamethasone—multiple sclerosis	0.000149	0.00373	CcSEcCtD
Pseudoephedrine—Asthenia—Mitoxantrone—multiple sclerosis	0.000147	0.00369	CcSEcCtD
Pseudoephedrine—Anxiety—Betamethasone—multiple sclerosis	0.000146	0.00366	CcSEcCtD
Pseudoephedrine—Anxiety—Dexamethasone—multiple sclerosis	0.000146	0.00366	CcSEcCtD
Pseudoephedrine—Pain—Prednisolone—multiple sclerosis	0.000144	0.00361	CcSEcCtD
Pseudoephedrine—Insomnia—Triamcinolone—multiple sclerosis	0.00014	0.00351	CcSEcCtD
Pseudoephedrine—Insomnia—Methylprednisolone—multiple sclerosis	0.00014	0.00351	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Prednisolone—multiple sclerosis	0.000139	0.00348	CcSEcCtD
Pseudoephedrine—Dyspnoea—Triamcinolone—multiple sclerosis	0.000138	0.00346	CcSEcCtD
Pseudoephedrine—Agitation—Prednisone—multiple sclerosis	0.000138	0.00346	CcSEcCtD
Pseudoephedrine—Tachycardia—Dexamethasone—multiple sclerosis	0.000137	0.00344	CcSEcCtD
Pseudoephedrine—Tachycardia—Betamethasone—multiple sclerosis	0.000137	0.00344	CcSEcCtD
Pseudoephedrine—Dyspepsia—Triamcinolone—multiple sclerosis	0.000136	0.00342	CcSEcCtD
Pseudoephedrine—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000136	0.00341	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000136	0.00341	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000136	0.00341	CcSEcCtD
Pseudoephedrine—Vertigo—Prednisone—multiple sclerosis	0.000135	0.00338	CcSEcCtD
Pseudoephedrine—Anorexia—Dexamethasone—multiple sclerosis	0.000134	0.00336	CcSEcCtD
Pseudoephedrine—Anorexia—Betamethasone—multiple sclerosis	0.000134	0.00336	CcSEcCtD
Pseudoephedrine—Pain—Triamcinolone—multiple sclerosis	0.000133	0.00332	CcSEcCtD
Pseudoephedrine—Vomiting—Mitoxantrone—multiple sclerosis	0.000131	0.00327	CcSEcCtD
Pseudoephedrine—Hypertension—Prednisone—multiple sclerosis	0.00013	0.00325	CcSEcCtD
Pseudoephedrine—Rash—Mitoxantrone—multiple sclerosis	0.00013	0.00325	CcSEcCtD
Pseudoephedrine—Dermatitis—Mitoxantrone—multiple sclerosis	0.000129	0.00324	CcSEcCtD
Pseudoephedrine—Headache—Mitoxantrone—multiple sclerosis	0.000129	0.00323	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000128	0.0032	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000127	0.00319	CcSEcCtD
Pseudoephedrine—Anxiety—Prednisone—multiple sclerosis	0.000127	0.00319	CcSEcCtD
Pseudoephedrine—Insomnia—Betamethasone—multiple sclerosis	0.000127	0.00319	CcSEcCtD
Pseudoephedrine—Insomnia—Dexamethasone—multiple sclerosis	0.000127	0.00319	CcSEcCtD
Pseudoephedrine—Dyspepsia—Dexamethasone—multiple sclerosis	0.000124	0.0031	CcSEcCtD
Pseudoephedrine—Dyspepsia—Betamethasone—multiple sclerosis	0.000124	0.0031	CcSEcCtD
Pseudoephedrine—Body temperature increased—Triamcinolone—multiple sclerosis	0.000123	0.00307	CcSEcCtD
Pseudoephedrine—Decreased appetite—Betamethasone—multiple sclerosis	0.000122	0.00306	CcSEcCtD
Pseudoephedrine—Decreased appetite—Dexamethasone—multiple sclerosis	0.000122	0.00306	CcSEcCtD
Pseudoephedrine—Nausea—Mitoxantrone—multiple sclerosis	0.000122	0.00306	CcSEcCtD
Pseudoephedrine—Pain—Dexamethasone—multiple sclerosis	0.00012	0.00301	CcSEcCtD
Pseudoephedrine—Pain—Betamethasone—multiple sclerosis	0.00012	0.00301	CcSEcCtD
Pseudoephedrine—Tachycardia—Prednisone—multiple sclerosis	0.00012	0.003	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Prednisone—multiple sclerosis	0.000118	0.00297	CcSEcCtD
Pseudoephedrine—Anorexia—Prednisone—multiple sclerosis	0.000117	0.00293	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Betamethasone—multiple sclerosis	0.000116	0.0029	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000116	0.0029	CcSEcCtD
Pseudoephedrine—Vertigo—Methotrexate—multiple sclerosis	0.000113	0.00282	CcSEcCtD
Pseudoephedrine—Dizziness—Prednisolone—multiple sclerosis	0.000111	0.00279	CcSEcCtD
Pseudoephedrine—Asthenia—Triamcinolone—multiple sclerosis	0.000111	0.00279	CcSEcCtD
Pseudoephedrine—Body temperature increased—Betamethasone—multiple sclerosis	0.000111	0.00279	CcSEcCtD
Pseudoephedrine—Body temperature increased—Dexamethasone—multiple sclerosis	0.000111	0.00279	CcSEcCtD
Pseudoephedrine—Asthenia—Methylprednisolone—multiple sclerosis	0.000111	0.00278	CcSEcCtD
Pseudoephedrine—Insomnia—Prednisone—multiple sclerosis	0.000111	0.00278	CcSEcCtD
Pseudoephedrine—Dyspepsia—Prednisone—multiple sclerosis	0.000108	0.0027	CcSEcCtD
Pseudoephedrine—Chest pain—Methotrexate—multiple sclerosis	0.000107	0.00268	CcSEcCtD
Pseudoephedrine—Decreased appetite—Prednisone—multiple sclerosis	0.000106	0.00267	CcSEcCtD
Pseudoephedrine—Rash—Prednisolone—multiple sclerosis	0.000106	0.00266	CcSEcCtD
Pseudoephedrine—Dermatitis—Prednisolone—multiple sclerosis	0.000106	0.00266	CcSEcCtD
Pseudoephedrine—Headache—Prednisolone—multiple sclerosis	0.000106	0.00265	CcSEcCtD
Pseudoephedrine—Confusional state—Methotrexate—multiple sclerosis	0.000103	0.00259	CcSEcCtD
Pseudoephedrine—Dizziness—Triamcinolone—multiple sclerosis	0.000103	0.00257	CcSEcCtD
Pseudoephedrine—Dizziness—Methylprednisolone—multiple sclerosis	0.000102	0.00256	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Prednisone—multiple sclerosis	0.000101	0.00253	CcSEcCtD
Pseudoephedrine—Asthenia—Dexamethasone—multiple sclerosis	0.000101	0.00253	CcSEcCtD
Pseudoephedrine—Asthenia—Betamethasone—multiple sclerosis	0.000101	0.00253	CcSEcCtD
Pseudoephedrine—Nausea—Prednisolone—multiple sclerosis	0.0001	0.00251	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Methotrexate—multiple sclerosis	9.9e-05	0.00248	CcSEcCtD
Pseudoephedrine—Vomiting—Triamcinolone—multiple sclerosis	9.86e-05	0.00247	CcSEcCtD
Pseudoephedrine—Vomiting—Methylprednisolone—multiple sclerosis	9.83e-05	0.00246	CcSEcCtD
Pseudoephedrine—Rash—Triamcinolone—multiple sclerosis	9.77e-05	0.00245	CcSEcCtD
Pseudoephedrine—Dermatitis—Triamcinolone—multiple sclerosis	9.77e-05	0.00245	CcSEcCtD
Pseudoephedrine—Anorexia—Methotrexate—multiple sclerosis	9.76e-05	0.00245	CcSEcCtD
Pseudoephedrine—Rash—Methylprednisolone—multiple sclerosis	9.75e-05	0.00244	CcSEcCtD
Pseudoephedrine—Dermatitis—Methylprednisolone—multiple sclerosis	9.74e-05	0.00244	CcSEcCtD
Pseudoephedrine—Headache—Triamcinolone—multiple sclerosis	9.71e-05	0.00243	CcSEcCtD
Pseudoephedrine—Headache—Methylprednisolone—multiple sclerosis	9.69e-05	0.00243	CcSEcCtD
Pseudoephedrine—Body temperature increased—Prednisone—multiple sclerosis	9.68e-05	0.00243	CcSEcCtD
Pseudoephedrine—Dizziness—Betamethasone—multiple sclerosis	9.3e-05	0.00233	CcSEcCtD
Pseudoephedrine—Dizziness—Dexamethasone—multiple sclerosis	9.3e-05	0.00233	CcSEcCtD
Pseudoephedrine—Insomnia—Methotrexate—multiple sclerosis	9.26e-05	0.00232	CcSEcCtD
Pseudoephedrine—Nausea—Triamcinolone—multiple sclerosis	9.21e-05	0.00231	CcSEcCtD
Pseudoephedrine—Nausea—Methylprednisolone—multiple sclerosis	9.19e-05	0.0023	CcSEcCtD
Pseudoephedrine—Dyspnoea—Methotrexate—multiple sclerosis	9.13e-05	0.00229	CcSEcCtD
Pseudoephedrine—Dyspepsia—Methotrexate—multiple sclerosis	9.01e-05	0.00226	CcSEcCtD
Pseudoephedrine—Vomiting—Betamethasone—multiple sclerosis	8.94e-05	0.00224	CcSEcCtD
Pseudoephedrine—Vomiting—Dexamethasone—multiple sclerosis	8.94e-05	0.00224	CcSEcCtD
Pseudoephedrine—Decreased appetite—Methotrexate—multiple sclerosis	8.9e-05	0.00223	CcSEcCtD
Pseudoephedrine—Rash—Betamethasone—multiple sclerosis	8.87e-05	0.00222	CcSEcCtD
Pseudoephedrine—Rash—Dexamethasone—multiple sclerosis	8.87e-05	0.00222	CcSEcCtD
Pseudoephedrine—Dermatitis—Betamethasone—multiple sclerosis	8.86e-05	0.00222	CcSEcCtD
Pseudoephedrine—Dermatitis—Dexamethasone—multiple sclerosis	8.86e-05	0.00222	CcSEcCtD
Pseudoephedrine—Headache—Dexamethasone—multiple sclerosis	8.81e-05	0.00221	CcSEcCtD
Pseudoephedrine—Headache—Betamethasone—multiple sclerosis	8.81e-05	0.00221	CcSEcCtD
Pseudoephedrine—Asthenia—Prednisone—multiple sclerosis	8.79e-05	0.0022	CcSEcCtD
Pseudoephedrine—Pain—Methotrexate—multiple sclerosis	8.75e-05	0.00219	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Methotrexate—multiple sclerosis	8.44e-05	0.00211	CcSEcCtD
Pseudoephedrine—Nausea—Betamethasone—multiple sclerosis	8.35e-05	0.00209	CcSEcCtD
Pseudoephedrine—Nausea—Dexamethasone—multiple sclerosis	8.35e-05	0.00209	CcSEcCtD
Pseudoephedrine—Dizziness—Prednisone—multiple sclerosis	8.1e-05	0.00203	CcSEcCtD
Pseudoephedrine—Body temperature increased—Methotrexate—multiple sclerosis	8.09e-05	0.00203	CcSEcCtD
Pseudoephedrine—Vomiting—Prednisone—multiple sclerosis	7.79e-05	0.00195	CcSEcCtD
Pseudoephedrine—Rash—Prednisone—multiple sclerosis	7.72e-05	0.00194	CcSEcCtD
Pseudoephedrine—Dermatitis—Prednisone—multiple sclerosis	7.72e-05	0.00193	CcSEcCtD
Pseudoephedrine—Headache—Prednisone—multiple sclerosis	7.67e-05	0.00192	CcSEcCtD
Pseudoephedrine—Asthenia—Methotrexate—multiple sclerosis	7.34e-05	0.00184	CcSEcCtD
Pseudoephedrine—Nausea—Prednisone—multiple sclerosis	7.28e-05	0.00182	CcSEcCtD
Pseudoephedrine—Dizziness—Methotrexate—multiple sclerosis	6.77e-05	0.0017	CcSEcCtD
Pseudoephedrine—Vomiting—Methotrexate—multiple sclerosis	6.51e-05	0.00163	CcSEcCtD
Pseudoephedrine—Rash—Methotrexate—multiple sclerosis	6.45e-05	0.00162	CcSEcCtD
Pseudoephedrine—Dermatitis—Methotrexate—multiple sclerosis	6.45e-05	0.00162	CcSEcCtD
Pseudoephedrine—Headache—Methotrexate—multiple sclerosis	6.41e-05	0.00161	CcSEcCtD
Pseudoephedrine—Nausea—Methotrexate—multiple sclerosis	6.08e-05	0.00152	CcSEcCtD
Pseudoephedrine—IL2—Signaling by GPCR—MAPK1—multiple sclerosis	1.32e-05	7.11e-05	CbGpPWpGaD
Pseudoephedrine—NFATC1—Disease—MAPK1—multiple sclerosis	1.32e-05	7.09e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—CNR1—multiple sclerosis	1.31e-05	7.07e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—RRM1—multiple sclerosis	1.31e-05	7.06e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Neuronal System—MAPK1—multiple sclerosis	1.31e-05	7.05e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CCR1—multiple sclerosis	1.31e-05	7.03e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CXCL13—multiple sclerosis	1.31e-05	7.03e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR downstream signaling—CXCL10—multiple sclerosis	1.3e-05	7.01e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—CCL3—multiple sclerosis	1.3e-05	7.01e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR downstream signaling—CCR2—multiple sclerosis	1.3e-05	6.98e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—PTGER4—multiple sclerosis	1.28e-05	6.91e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—PTGER4—multiple sclerosis	1.25e-05	6.75e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—RGS1—multiple sclerosis	1.25e-05	6.7e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—CXCR3—multiple sclerosis	1.24e-05	6.67e-05	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—TYK2—multiple sclerosis	1.23e-05	6.6e-05	CbGpPWpGaD
Pseudoephedrine—SLC6A3—Neuronal System—MAPK1—multiple sclerosis	1.22e-05	6.55e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—IL2RA—multiple sclerosis	1.21e-05	6.52e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—CXCR3—multiple sclerosis	1.21e-05	6.52e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—CCL3—multiple sclerosis	1.21e-05	6.51e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—CXCL10—multiple sclerosis	1.21e-05	6.51e-05	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—MAPK1—multiple sclerosis	1.21e-05	6.5e-05	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—IL2—multiple sclerosis	1.21e-05	6.49e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—CCR2—multiple sclerosis	1.21e-05	6.49e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR downstream signaling—CNR1—multiple sclerosis	1.2e-05	6.44e-05	CbGpPWpGaD
Pseudoephedrine—SLC6A2—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.19e-05	6.41e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—CXCL10—multiple sclerosis	1.18e-05	6.37e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—GPR65—multiple sclerosis	1.18e-05	6.36e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—CCR2—multiple sclerosis	1.18e-05	6.34e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—PTGER4—multiple sclerosis	1.17e-05	6.27e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	1.16e-05	6.24e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—RGS1—multiple sclerosis	1.16e-05	6.23e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR ligand binding—POMC—multiple sclerosis	1.16e-05	6.22e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR downstream signaling—CCL5—multiple sclerosis	1.15e-05	6.17e-05	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—MMP9—multiple sclerosis	1.14e-05	6.15e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR ligand binding—CCL2—multiple sclerosis	1.13e-05	6.09e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	1.13e-05	6.07e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	1.13e-05	6.07e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—BCHE—multiple sclerosis	1.13e-05	6.07e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—CXCR3—multiple sclerosis	1.13e-05	6.06e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR downstream signaling—CCL5—multiple sclerosis	1.12e-05	6.04e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—CNR1—multiple sclerosis	1.11e-05	5.99e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—GPR65—multiple sclerosis	1.1e-05	5.9e-05	CbGpPWpGaD
Pseudoephedrine—NFATC1—Immune System—IL6—multiple sclerosis	1.1e-05	5.9e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—CCR2—multiple sclerosis	1.09e-05	5.89e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—CNR1—multiple sclerosis	1.09e-05	5.85e-05	CbGpPWpGaD
Pseudoephedrine—TNF—Developmental Biology—MMP9—multiple sclerosis	1.08e-05	5.82e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CCR1—multiple sclerosis	1.08e-05	5.81e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CXCL13—multiple sclerosis	1.08e-05	5.81e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR downstream signaling—CXCL10—multiple sclerosis	1.08e-05	5.8e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	1.07e-05	5.78e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR ligand binding—POMC—multiple sclerosis	1.07e-05	5.78e-05	CbGpPWpGaD
Pseudoephedrine—SLC6A3—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.05e-05	5.68e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	1.05e-05	5.67e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR ligand binding—CCL2—multiple sclerosis	1.05e-05	5.66e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—CCL5—multiple sclerosis	1.04e-05	5.61e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR downstream signaling—CCR5—multiple sclerosis	1.03e-05	5.56e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—GPC5—multiple sclerosis	1.03e-05	5.55e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—CCL5—multiple sclerosis	1.02e-05	5.48e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR downstream signaling—IL2RA—multiple sclerosis	1.02e-05	5.48e-05	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling by GPCR—IL6—multiple sclerosis	1.02e-05	5.47e-05	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—STAT3—multiple sclerosis	1.02e-05	5.47e-05	CbGpPWpGaD
Pseudoephedrine—NFATC1—Disease—IL6—multiple sclerosis	1.01e-05	5.45e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR downstream signaling—CCR5—multiple sclerosis	1.01e-05	5.44e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—CNR1—multiple sclerosis	1.01e-05	5.44e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CCR1—multiple sclerosis	1e-05	5.4e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CXCL13—multiple sclerosis	1e-05	5.4e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—CXCL10—multiple sclerosis	1e-05	5.39e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR downstream signaling—IL2RA—multiple sclerosis	9.96e-06	5.36e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—CXCL10—multiple sclerosis	9.79e-06	5.27e-05	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—MMP9—multiple sclerosis	9.66e-06	5.2e-05	CbGpPWpGaD
Pseudoephedrine—TNF—Developmental Biology—STAT3—multiple sclerosis	9.61e-06	5.17e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CCL3—multiple sclerosis	9.51e-06	5.12e-05	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—MYC—multiple sclerosis	9.43e-06	5.08e-05	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—TGFB1—multiple sclerosis	9.41e-06	5.07e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—CCR5—multiple sclerosis	9.38e-06	5.05e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CCL3—multiple sclerosis	9.3e-06	5.01e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR downstream signaling—CCL5—multiple sclerosis	9.28e-06	4.99e-05	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—IL6—multiple sclerosis	9.28e-06	4.99e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—IL2RA—multiple sclerosis	9.25e-06	4.98e-05	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—MAPK1—multiple sclerosis	9.23e-06	4.97e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—CCR5—multiple sclerosis	9.18e-06	4.94e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PTGER4—multiple sclerosis	9.15e-06	4.93e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—CXCL10—multiple sclerosis	9.1e-06	4.9e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—IL2RA—multiple sclerosis	9.05e-06	4.87e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PGR—multiple sclerosis	9.02e-06	4.85e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PTGER4—multiple sclerosis	8.96e-06	4.82e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	8.91e-06	4.8e-05	CbGpPWpGaD
Pseudoephedrine—TNF—Developmental Biology—TGFB1—multiple sclerosis	8.91e-06	4.79e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CXCR3—multiple sclerosis	8.84e-06	4.76e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PGR—multiple sclerosis	8.82e-06	4.75e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CD28—multiple sclerosis	8.76e-06	4.71e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—ALB—multiple sclerosis	8.76e-06	4.71e-05	CbGpPWpGaD
Pseudoephedrine—TNF—Developmental Biology—MAPK1—multiple sclerosis	8.73e-06	4.7e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CXCR3—multiple sclerosis	8.65e-06	4.66e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—CCL5—multiple sclerosis	8.62e-06	4.64e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CCR2—multiple sclerosis	8.6e-06	4.63e-05	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—STAT3—multiple sclerosis	8.59e-06	4.62e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CD28—multiple sclerosis	8.57e-06	4.61e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—RRM1—multiple sclerosis	8.55e-06	4.6e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—CCL5—multiple sclerosis	8.43e-06	4.54e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CCR2—multiple sclerosis	8.41e-06	4.53e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR downstream signaling—CCR5—multiple sclerosis	8.36e-06	4.5e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR downstream signaling—IL2RA—multiple sclerosis	8.24e-06	4.43e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR downstream signaling—POMC—multiple sclerosis	8.07e-06	4.35e-05	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—MYC—multiple sclerosis	7.98e-06	4.3e-05	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—TGFB1—multiple sclerosis	7.96e-06	4.28e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CNR1—multiple sclerosis	7.94e-06	4.27e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR downstream signaling—POMC—multiple sclerosis	7.9e-06	4.25e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—CCL5—multiple sclerosis	7.83e-06	4.21e-05	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—MAPK1—multiple sclerosis	7.81e-06	4.2e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—CCR5—multiple sclerosis	7.77e-06	4.18e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CNR1—multiple sclerosis	7.76e-06	4.18e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CCL3—multiple sclerosis	7.7e-06	4.14e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—IL2RA—multiple sclerosis	7.65e-06	4.12e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—CCR5—multiple sclerosis	7.59e-06	4.09e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—BCHE—multiple sclerosis	7.54e-06	4.06e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—IL2RA—multiple sclerosis	7.48e-06	4.03e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PTGER4—multiple sclerosis	7.41e-06	3.99e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—POMC—multiple sclerosis	7.33e-06	3.95e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PGR—multiple sclerosis	7.29e-06	3.93e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—CCL2—multiple sclerosis	7.17e-06	3.86e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—POMC—multiple sclerosis	7.17e-06	3.86e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CXCR3—multiple sclerosis	7.15e-06	3.85e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CCL3—multiple sclerosis	7.15e-06	3.85e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CXCL10—multiple sclerosis	7.15e-06	3.85e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—IL2—multiple sclerosis	7.1e-06	3.82e-05	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—IL6—multiple sclerosis	7.09e-06	3.82e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CD28—multiple sclerosis	7.09e-06	3.81e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—CCR5—multiple sclerosis	7.05e-06	3.8e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—CCL2—multiple sclerosis	7.02e-06	3.78e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CXCL10—multiple sclerosis	6.99e-06	3.76e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CCR2—multiple sclerosis	6.96e-06	3.75e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—IL2RA—multiple sclerosis	6.95e-06	3.74e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PTGER4—multiple sclerosis	6.88e-06	3.7e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—APOE—multiple sclerosis	6.79e-06	3.65e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PGR—multiple sclerosis	6.78e-06	3.65e-05	CbGpPWpGaD
Pseudoephedrine—TNF—Developmental Biology—IL6—multiple sclerosis	6.71e-06	3.61e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CXCR3—multiple sclerosis	6.65e-06	3.58e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CD28—multiple sclerosis	6.58e-06	3.54e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR downstream signaling—POMC—multiple sclerosis	6.53e-06	3.52e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—TYK2—multiple sclerosis	6.51e-06	3.51e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CCR2—multiple sclerosis	6.47e-06	3.48e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CNR1—multiple sclerosis	6.42e-06	3.46e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—TYK2—multiple sclerosis	6.37e-06	3.43e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CD86—multiple sclerosis	6.25e-06	3.36e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CCL5—multiple sclerosis	6.15e-06	3.31e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CD86—multiple sclerosis	6.11e-06	3.29e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—POMC—multiple sclerosis	6.07e-06	3.27e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CCL5—multiple sclerosis	6.02e-06	3.24e-05	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—IL6—multiple sclerosis	6e-06	3.23e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR downstream signaling—IL2—multiple sclerosis	5.97e-06	3.21e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CNR1—multiple sclerosis	5.97e-06	3.21e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—POMC—multiple sclerosis	5.93e-06	3.19e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR downstream signaling—IL2—multiple sclerosis	5.84e-06	3.14e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—POMC—multiple sclerosis	5.83e-06	3.14e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—CCL2—multiple sclerosis	5.81e-06	3.12e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CXCL10—multiple sclerosis	5.78e-06	3.11e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—SPP1—multiple sclerosis	5.7e-06	3.07e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—SPP1—multiple sclerosis	5.57e-06	3e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CCR5—multiple sclerosis	5.54e-06	2.98e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—TGFB1—multiple sclerosis	5.54e-06	2.98e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—POMC—multiple sclerosis	5.51e-06	2.97e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—IL2RA—multiple sclerosis	5.46e-06	2.94e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—MAPK1—multiple sclerosis	5.43e-06	2.92e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CCR5—multiple sclerosis	5.42e-06	2.92e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—IL2—multiple sclerosis	5.42e-06	2.92e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—CCL2—multiple sclerosis	5.39e-06	2.9e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CXCL10—multiple sclerosis	5.37e-06	2.89e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—IL2RA—multiple sclerosis	5.34e-06	2.88e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—ALB—multiple sclerosis	5.31e-06	2.86e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—IL2—multiple sclerosis	5.3e-06	2.85e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—TYK2—multiple sclerosis	5.27e-06	2.84e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CD86—multiple sclerosis	5.06e-06	2.72e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—APOE—multiple sclerosis	5.04e-06	2.71e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CCL5—multiple sclerosis	4.98e-06	2.68e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—APOE—multiple sclerosis	4.93e-06	2.65e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—BCHE—multiple sclerosis	4.91e-06	2.64e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—TYK2—multiple sclerosis	4.9e-06	2.64e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR downstream signaling—IL2—multiple sclerosis	4.83e-06	2.6e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CD86—multiple sclerosis	4.7e-06	2.53e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CCL5—multiple sclerosis	4.62e-06	2.49e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—SPP1—multiple sclerosis	4.61e-06	2.48e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CD80—multiple sclerosis	4.56e-06	2.45e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—APOE—multiple sclerosis	4.53e-06	2.44e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—IL2—multiple sclerosis	4.49e-06	2.42e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CCR5—multiple sclerosis	4.48e-06	2.41e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CD80—multiple sclerosis	4.46e-06	2.4e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—IL2RA—multiple sclerosis	4.42e-06	2.38e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—IL2—multiple sclerosis	4.39e-06	2.36e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—POMC—multiple sclerosis	4.33e-06	2.33e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—SPP1—multiple sclerosis	4.28e-06	2.31e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CCL2—multiple sclerosis	4.24e-06	2.28e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—POMC—multiple sclerosis	4.24e-06	2.28e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CCR5—multiple sclerosis	4.17e-06	2.24e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—MAPK1—multiple sclerosis	4.15e-06	2.23e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CCL2—multiple sclerosis	4.15e-06	2.23e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—IL2RA—multiple sclerosis	4.11e-06	2.21e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—APOE—multiple sclerosis	4.08e-06	2.2e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—IL2—multiple sclerosis	4.08e-06	2.19e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—MAPK1—multiple sclerosis	4.06e-06	2.18e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—POMC—multiple sclerosis	3.89e-06	2.1e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—TYK2—multiple sclerosis	3.85e-06	2.07e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—APOE—multiple sclerosis	3.79e-06	2.04e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—TYK2—multiple sclerosis	3.76e-06	2.03e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CD80—multiple sclerosis	3.69e-06	1.99e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—ALB—multiple sclerosis	3.55e-06	1.91e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—POMC—multiple sclerosis	3.5e-06	1.89e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CCL2—multiple sclerosis	3.43e-06	1.85e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CD80—multiple sclerosis	3.43e-06	1.84e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—MAPK1—multiple sclerosis	3.36e-06	1.81e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—POMC—multiple sclerosis	3.26e-06	1.75e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—IL2—multiple sclerosis	3.2e-06	1.72e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—IL6—multiple sclerosis	3.19e-06	1.71e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CCL2—multiple sclerosis	3.19e-06	1.71e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—IL2—multiple sclerosis	3.13e-06	1.69e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—MAPK1—multiple sclerosis	3.12e-06	1.68e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—IL6—multiple sclerosis	3.12e-06	1.68e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—TYK2—multiple sclerosis	3.11e-06	1.68e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MMP9—multiple sclerosis	3.03e-06	1.63e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MMP9—multiple sclerosis	2.96e-06	1.6e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—APOE—multiple sclerosis	2.95e-06	1.59e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—TYK2—multiple sclerosis	2.89e-06	1.56e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—STAT3—multiple sclerosis	2.69e-06	1.45e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—STAT3—multiple sclerosis	2.64e-06	1.42e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—IL2—multiple sclerosis	2.59e-06	1.39e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—IL6—multiple sclerosis	2.58e-06	1.39e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—POMC—multiple sclerosis	2.54e-06	1.37e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MYC—multiple sclerosis	2.5e-06	1.35e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—TGFB1—multiple sclerosis	2.5e-06	1.34e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MMP9—multiple sclerosis	2.45e-06	1.32e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MAPK1—multiple sclerosis	2.45e-06	1.32e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MYC—multiple sclerosis	2.45e-06	1.32e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—TGFB1—multiple sclerosis	2.44e-06	1.32e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—IL2—multiple sclerosis	2.41e-06	1.3e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MAPK1—multiple sclerosis	2.4e-06	1.29e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—IL6—multiple sclerosis	2.4e-06	1.29e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—ALB—multiple sclerosis	2.31e-06	1.25e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MMP9—multiple sclerosis	2.28e-06	1.23e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—STAT3—multiple sclerosis	2.18e-06	1.17e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MYC—multiple sclerosis	2.03e-06	1.09e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—STAT3—multiple sclerosis	2.03e-06	1.09e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—TGFB1—multiple sclerosis	2.02e-06	1.09e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MAPK1—multiple sclerosis	1.98e-06	1.07e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MYC—multiple sclerosis	1.88e-06	1.01e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—IL6—multiple sclerosis	1.88e-06	1.01e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—TGFB1—multiple sclerosis	1.88e-06	1.01e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MAPK1—multiple sclerosis	1.84e-06	9.91e-06	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—IL6—multiple sclerosis	1.84e-06	9.91e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—IL6—multiple sclerosis	1.52e-06	8.2e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—IL6—multiple sclerosis	1.42e-06	7.62e-06	CbGpPWpGaD
